Condition Lookup

Hypertension (High Blood Pressure)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Polygenic and Multifactorial Disorders

Symptoms:
often asymptomatic; headaches; shortness of breath; nosebleeds (in severe cases)

Root Cause:
Persistent elevation of blood pressure due to genetic predisposition, environmental factors, and secondary causes (e.g., kidney disease, endocrine disorders).

How it's Diagnosed: videos
Blood pressure measurements, repeated over time; additional tests for secondary causes.

Treatment:
Lifestyle changes (dietary adjustments like reduced salt intake, weight loss, exercise) and antihypertensive medications.

Medications:
Diuretics (e.g., hydrochlorothiazide ) to reduce fluid retention. ACE inhibitors (e.g., enalapril ) or ARBs (e.g., losartan ) to relax blood vessels. Calcium channel blockers (e.g., amlodipine ). Beta-blockers (e.g., propranolol ).

Prevalence: How common the health condition is within a specific population.
Affects about 1.28 billion adults worldwide, with a higher prevalence in older populations.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, obesity, high salt intake, physical inactivity, stress, alcohol consumption, age.

Prognosis: The expected outcome or course of the condition over time.
With proper management, patients can maintain normal blood pressure and prevent complications. Uncontrolled hypertension increases the risk of cardiovascular and renal diseases.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Stroke, heart attack, heart failure, kidney failure, vision loss, aneurysms.

Coronary Artery Disease

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Polygenic and Multifactorial Disorders

Symptoms:
chest pain or discomfort (angina); shortness of breath; fatigue; heart attack symptoms such as severe chest pain, sweating, and nausea

Root Cause:
Buildup of plaque (atherosclerosis) in the coronary arteries, leading to reduced blood flow to the heart. Genetic predispositions combined with lifestyle factors exacerbate the risk.

How it's Diagnosed: videos
Electrocardiogram (ECG), stress tests, echocardiography, coronary angiography, and blood tests for cholesterol and cardiac enzymes.

Treatment:
Lifestyle changes (diet, exercise, smoking cessation), medications, and surgical interventions like angioplasty or coronary artery bypass grafting (CABG).

Medications:
Statins (e.g., atorvastatin ) to lower cholesterol. Antiplatelets (e.g., aspirin , clopidogrel ) to prevent clot formation. Beta-blockers (e.g., metoprolol ) to reduce heart workload. ACE inhibitors (e.g., lisinopril ) to lower blood pressure and protect the heart. Nitroglycerin for angina relief.

Prevalence: How common the health condition is within a specific population.
The leading cause of death worldwide, affecting millions annually. Prevalence increases with age.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, smoking, high cholesterol, high blood pressure, diabetes, obesity, physical inactivity.

Prognosis: The expected outcome or course of the condition over time.
With treatment and lifestyle modifications, CAD can be managed, though it remains a lifelong condition. Untreated, it can lead to fatal heart attacks.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Heart attack, heart failure, arrhythmias, sudden cardiac death.

Marfan Syndrome (FBN1 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Dominant Disorders

Symptoms:
tall stature; long limbs and fingers; scoliosis; pectus excavatum or pectus carinatum; lens dislocation; aortic aneurysm or dissection; mitral valve prolapse; joint hypermobility

Root Cause:
Mutation in the FBN1 gene causing defective fibrillin-1, a structural protein essential for connective tissue integrity.

How it's Diagnosed: videos
Clinical examination, family history, echocardiography for aortic dilation, genetic testing for FBN1 mutations.

Treatment:
Regular monitoring of cardiovascular health, surgical repair of aortic aneurysms if indicated, physical therapy for joint issues, vision correction.

Medications:
Beta-blockers (e.g., propranolol ) to reduce stress on the aorta, or angiotensin receptor blockers (ARBs) like losartan , which may help prevent aortic dilation.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 5,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of Marfan syndrome, being born to a parent with the FBN1 mutation (50% inheritance risk).

Prognosis: The expected outcome or course of the condition over time.
With proper management and monitoring, individuals can have a near-normal lifespan.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Aortic dissection, heart failure, severe scoliosis, retinal detachment, pneumothorax.

Neurofibromatosis Type 1 (NF1 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Dominant Disorders

Symptoms:
café-au-lait spots; neurofibromas; axillary or inguinal freckling; lisch nodules (iris hamartomas); optic gliomas; learning disabilities; scoliosis

Root Cause:
Mutation in the NF1 gene causing loss of neurofibromin, a tumor suppressor protein.

How it's Diagnosed: videos
Clinical diagnostic criteria (greather than 6 café-au-lait spots, greater than 2 neurofibromas, or other features), MRI for optic gliomas, genetic testing for NF1 mutations.

Treatment:
Symptom-based management, surgical removal of problematic neurofibromas, early intervention for learning disabilities.

Medications:
Selumetinib , a MEK inhibitor, may be used to reduce the size of plexiform neurofibromas.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 3,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, 50% inheritance risk from an affected parent.

Prognosis: The expected outcome or course of the condition over time.
Highly variable; most individuals live normal lifespans, but severe complications may arise.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Malignant transformation of neurofibromas, scoliosis, optic pathway gliomas.

Neurofibromatosis Type 2 (NF2 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Dominant Disorders

Symptoms:
bilateral vestibular schwannomas (hearing loss, tinnitus, balance issues); meningiomas; schwannomas in other nerves; vision changes from cataracts

Root Cause:
Mutation in the NF2 gene resulting in loss of merlin (schwannomin), a tumor suppressor protein.

How it's Diagnosed: videos
MRI of the brain and spine, auditory testing, genetic testing for NF2 mutations.

Treatment:
Surgical removal or radiation of tumors, auditory rehabilitation, vision correction for cataracts.

Medications:
Bevacizumab , an angiogenesis inhibitor, may reduce the size of vestibular schwannomas.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 25,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of NF2, 50% inheritance risk from an affected parent.

Prognosis: The expected outcome or course of the condition over time.
Progressive condition; early treatment improves quality of life.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Hearing loss, facial nerve paralysis, spinal cord compression.

Huntington’s Disease (HTT gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Dominant Disorders

Symptoms:
progressive movement disorders (chorea, dystonia); cognitive decline; psychiatric symptoms (depression, irritability, apathy); difficulty with coordination; speech and swallowing difficulties

Root Cause:
Expansion of CAG trinucleotide repeats in the HTT gene, leading to toxic accumulation of mutant huntingtin protein in neurons.

How it's Diagnosed: videos
Genetic testing confirming expanded CAG repeats, clinical evaluation of motor, cognitive, and psychiatric symptoms, family history.

Treatment:
Symptom management with multidisciplinary care including neurology, psychiatry, and physical therapy.

Medications:
Tetrabenazine or deutetrabenazine for chorea; antidepressants (SSRIs) and antipsychotics for psychiatric symptoms.

Prevalence: How common the health condition is within a specific population.
Affects approximately 3 to 7 per 100,000 individuals of European descent.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of Huntington’s disease; 50% inheritance risk for children of an affected parent.

Prognosis: The expected outcome or course of the condition over time.
Progressive and fatal disease; average survival is 15–20 years after symptom onset.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Aspiration pneumonia, malnutrition, injury from falls, severe cognitive and psychiatric impairment.

Achondroplasia (FGFR3 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Dominant Disorders

Symptoms:
short stature; disproportionately short limbs; macrocephaly; frontal bossing; midface hypoplasia; spinal stenosis; bowed legs

Root Cause:
Gain-of-function mutation in the FGFR3 gene, leading to impaired cartilage formation and bone growth.

How it's Diagnosed: videos
Clinical examination, radiographic findings, genetic testing for FGFR3 mutations.

Treatment:
Symptom management with physical therapy, surgical intervention for spinal stenosis or severe deformities, growth hormone therapy (under investigation).

Medications:
Vosoritide , a C-type natriuretic peptide analog, to promote bone growth in children.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 15,000–40,000 live births.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Advanced paternal age increases the risk of new mutations; 50% inheritance risk from an affected parent.

Prognosis: The expected outcome or course of the condition over time.
Normal lifespan with appropriate management; potential for complications requiring intervention.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Foramen magnum compression, spinal cord compression, recurrent ear infections, sleep apnea.

Familial Hypercholesterolemia (LDLR gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Dominant Disorders

Symptoms:
elevated ldl cholesterol; xanthomas (cholesterol deposits in tendons); xanthelasmas (yellowish deposits around eyelids); premature coronary artery disease

Root Cause:
Mutation in the LDLR gene causing reduced clearance of LDL cholesterol from the bloodstream.

How it's Diagnosed: videos
Lipid profile showing high LDL cholesterol, genetic testing for LDLR mutations, family history of early cardiovascular disease.

Treatment:
Lifestyle changes (diet, exercise), lipid-lowering therapies, and monitoring for cardiovascular complications.

Medications:
Statins (e.g., atorvastatin , rosuvastatin ), PCSK9 inhibitors (e.g., evolocumab , alirocumab ), ezetimibe , and bile acid sequestrants.

Prevalence: How common the health condition is within a specific population.
Heterozygous form affects 1 in 250 individuals; homozygous form is rarer (~1 in 1 million).

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of familial hypercholesterolemia; 50% inheritance risk in heterozygotes.

Prognosis: The expected outcome or course of the condition over time.
Lifelong risk of cardiovascular disease; early treatment can significantly improve outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Myocardial infarction, stroke, peripheral artery disease.

Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2 mutations)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Dominant Disorders

Symptoms:
early-onset breast cancer; ovarian cancer; pancreatic cancer; prostate cancer in males; multiple primary cancers in the same individual

Root Cause:
Mutations in BRCA1 or BRCA2 genes impair DNA repair mechanisms, leading to increased susceptibility to cancer.

How it's Diagnosed: videos
Genetic testing for BRCA1/BRCA2 mutations, family history of cancers, tumor testing for somatic BRCA mutations.

Treatment:
Cancer screening and prevention (e.g., mammography, transvaginal ultrasound), risk-reducing surgery (mastectomy, oophorectomy), targeted cancer therapies.

Medications:
PARP inhibitors (e.g., olaparib , rucaparib ) for cancers associated with BRCA mutations.

Prevalence: How common the health condition is within a specific population.
Approximately 1 in 400 individuals carries a BRCA mutation; higher prevalence in certain populations (e.g., Ashkenazi Jews).

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of BRCA-related cancers; 50% inheritance risk from an affected parent.

Prognosis: The expected outcome or course of the condition over time.
With early detection and management, outcomes can be significantly improved.

Complications: Additional problems or conditions that may arise as a result of the original condition.
High risk of metastatic cancer, secondary cancers.

Cystic fibrosis (CFTR gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Recessive Disorders

Symptoms:
persistent coughing with phlegm; frequent lung infections; shortness of breath; salty-tasting skin; poor growth or weight gain; greasy, bulky stools; male infertility

Root Cause:
Mutations in the CFTR gene lead to defective or absent CFTR protein, resulting in thick, sticky mucus in the lungs, pancreas, and other organs.

How it's Diagnosed: videos
Sweat chloride test, genetic testing for CFTR mutations, newborn screening, pulmonary function tests, and imaging (e.g., chest X-ray).

Treatment:
Airway clearance techniques, physical therapy, nutritional support, lung transplant in severe cases.

Medications:
CFTR modulators (e.g., ivacaftor , lumacaftor /ivacaftor ), bronchodilators, mucolytics (e.g., dornase alfa), antibiotics for lung infections (e.g., tobramycin , azithromycin ), pancreatic enzyme replacement therapy.

Prevalence: How common the health condition is within a specific population.
Affects approximately 70,000 individuals worldwide; most common in people of Northern European descent.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, being of Northern European ancestry.

Prognosis: The expected outcome or course of the condition over time.
Life expectancy has improved significantly with advancements in treatment; median survival is around 40–50 years.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Chronic respiratory failure, diabetes, osteoporosis, infertility, liver disease.

Sickle cell disease (HBB gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Recessive Disorders

Symptoms:
anemia; pain episodes (sickle cell crises); swelling in hands and feet; frequent infections; delayed growth; vision problems

Root Cause:
Mutations in the HBB gene cause abnormal hemoglobin (HbS), leading to red blood cells becoming sickle-shaped and prone to clumping.

How it's Diagnosed: videos
Hemoglobin electrophoresis, genetic testing for HBB mutations, newborn screening.

Treatment:
Blood transfusions, bone marrow transplant, pain management, and prevention of infections.

Medications:
Hydroxyurea (stimulates fetal hemoglobin production), L-glutamine (reduces oxidative stress), crizanlizumab (reduces pain crises), voxelotor (improves hemoglobin levels).

Prevalence: How common the health condition is within a specific population.
Approximately 300,000 births annually worldwide; more common in individuals of African, Mediterranean, Middle Eastern, and Indian ancestry.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, being of African or Mediterranean descent.

Prognosis: The expected outcome or course of the condition over time.
Variable; with proper treatment, many patients live into their 40s or 50s, though complications may arise.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Stroke, organ damage, acute chest syndrome, infections, leg ulcers.

Tay-Sachs disease (HEXA gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Recessive Disorders

Symptoms:
loss of motor skills; muscle weakness; seizures; exaggerated startle response; vision and hearing loss; cherry-red spot on the retina

Root Cause:
Mutations in the HEXA gene lead to a deficiency of beta-hexosaminidase A, causing accumulation of GM2 gangliosides in nerve cells.

How it's Diagnosed: videos
Enzyme activity assay for beta-hexosaminidase A, genetic testing for HEXA mutations, prenatal testing for carriers.

Treatment:
Currently no cure; supportive care includes managing symptoms, physical therapy, and nutritional support.

Medications:
No specific medications; anticonvulsants for seizures, supportive therapies.

Prevalence: How common the health condition is within a specific population.
Most common in Ashkenazi Jewish populations, with a carrier frequency of 1 in 30.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Ashkenazi Jewish, French-Canadian, or Cajun ancestry; family history of Tay-Sachs.

Prognosis: The expected outcome or course of the condition over time.
Poor; infantile form leads to death by age 4–5.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Progressive neurological decline, respiratory infections, feeding difficulties.

Phenylketonuria (PAH gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Recessive Disorders

Symptoms:
intellectual disability; seizures; musty odor in breath, skin, or urine; behavioral problems; eczema; delayed developmental milestones

Root Cause:
Mutations in the PAH gene result in deficient phenylalanine hydroxylase, leading to the accumulation of phenylalanine in the blood and toxic effects on the brain.

How it's Diagnosed: videos
Newborn screening via blood test (measuring phenylalanine levels), genetic testing for PAH mutations.

Treatment:
Lifelong low-phenylalanine diet, special medical formulas, and newer enzyme substitution therapies.

Medications:
Sapropterin dihydrochloride (BH4 cofactor to reduce phenylalanine levels), pegvaliase (enzyme replacement therapy).

Prevalence: How common the health condition is within a specific population.
Approximately 1 in 10,000 to 1 in 15,000 live births worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history; higher prevalence in European and Asian populations.

Prognosis: The expected outcome or course of the condition over time.
Good with early and lifelong treatment; untreated cases result in severe intellectual disability and neurological damage.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Severe intellectual disability, seizures, behavioral problems, psychiatric disorders.

Wilson disease (ATP7B gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Recessive Disorders

Symptoms:
jaundice; abdominal pain; swelling in legs and abdomen; neurological symptoms like tremors or poor coordination; psychiatric symptoms; kayser-fleischer rings in the eyes

Root Cause:
Mutations in the ATP7B gene impair copper transport, leading to copper accumulation in the liver, brain, and other tissues.

How it's Diagnosed: videos
Serum ceruloplasmin levels, 24-hour urine copper test, liver biopsy, genetic testing for ATP7B mutations, slit-lamp exam for Kayser-Fleischer rings.

Treatment:
Copper-chelating agents, dietary modifications to reduce copper intake, and liver transplantation in severe cases.

Medications:
Penicillamine (chelates copper), trientine (alternative chelating agent), zinc acetate (reduces copper absorption).

Prevalence: How common the health condition is within a specific population.
Affects 1 in 30,000 to 1 in 40,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history; no specific demographic predisposition.

Prognosis: The expected outcome or course of the condition over time.
Good with early treatment; untreated cases result in severe liver and neurological damage.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Liver failure, neurological impairment, psychiatric disorders.

Alpha-1 antitrypsin deficiency (SERPINA1 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Autosomal Recessive Disorders

Symptoms:
shortness of breath; chronic cough; wheezing; recurrent respiratory infections; jaundice; liver disease

Root Cause:
Mutations in the SERPINA1 gene lead to low or dysfunctional alpha-1 antitrypsin protein, causing lung damage from uninhibited neutrophil elastase and liver damage due to protein accumulation.

How it's Diagnosed: videos
Blood test measuring alpha-1 antitrypsin levels, genetic testing for SERPINA1 mutations, imaging for lung damage (e.g., CT scan), liver function tests.

Treatment:
Lifestyle changes (e.g., avoiding smoking), augmentation therapy with alpha-1 antitrypsin, and, in severe cases, lung or liver transplantation.

Medications:
Alpha-1 antitrypsin protein (augmentation therapy), bronchodilators, corticosteroids for lung inflammation.

Prevalence: How common the health condition is within a specific population.
Affects 1 in 2,500 to 1 in 5,000 individuals of European descent.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history; higher prevalence in Northern European populations.

Prognosis: The expected outcome or course of the condition over time.
Variable; better with early diagnosis and lifestyle modifications. Without treatment, may lead to early-onset COPD or liver disease.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Early-onset emphysema, liver cirrhosis, hepatocellular carcinoma.

Duchenne muscular dystrophy (DMD gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: X-Linked Disorders

Symptoms:
progressive muscle weakness; delayed motor milestones; difficulty climbing stairs; waddling gait; calf pseudohypertrophy; respiratory complications; cardiomyopathy

Root Cause:
Mutations in the DMD gene lead to the absence or deficiency of dystrophin, a protein essential for muscle integrity.

How it's Diagnosed: videos
Clinical evaluation, elevated creatine kinase (CK) levels, genetic testing for DMD mutations, muscle biopsy (rarely used).

Treatment:
Physical therapy, corticosteroids, assistive devices, multidisciplinary care (including cardiology and respiratory specialists).

Medications:
Prednisone or deflazacort (corticosteroids) to slow muscle degeneration; exon-skipping drugs like eteplirsen for specific mutations.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 3,500 to 5,000 male births worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of DMD mutations; primarily affects males due to X-linked inheritance.

Prognosis: The expected outcome or course of the condition over time.
Progressive and life-limiting; survival often into the 20s or 30s with advanced care.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Respiratory failure, heart failure, scoliosis, contractures, and reduced mobility.

Hemophilia A (F8 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: X-Linked Disorders

Symptoms:
spontaneous bleeding; prolonged bleeding after injuries or surgeries; joint swelling and pain; easy bruising

Root Cause:
Mutations in the F8 gene lead to deficiency or dysfunction of clotting factor VIII, impairing blood clotting.

How it's Diagnosed: videos
Coagulation tests (prolonged activated partial thromboplastin time), factor VIII activity assays, genetic testing.

Treatment:
Regular infusion of recombinant or plasma-derived factor VIII concentrates; prophylactic therapy to prevent bleeding episodes.

Medications:
Emicizumab (monoclonal antibody for prophylaxis), desmopressin (for mild cases), clotting factor concentrates (recombinant or plasma-derived).

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 5,000 male births worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of hemophilia A; primarily affects males due to X-linked inheritance.

Prognosis: The expected outcome or course of the condition over time.
With appropriate treatment, individuals can lead relatively normal lives; untreated, can result in severe disability or death.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Joint damage from repeated bleeding, inhibitor formation (antibodies to factor VIII), intracranial hemorrhage.

Hemophilia B (F9 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: X-Linked Disorders

Symptoms:
spontaneous bleeding; prolonged bleeding after injuries or surgeries; joint swelling and pain; easy bruising

Root Cause:
Mutations in the F9 gene lead to deficiency or dysfunction of clotting factor IX, impairing blood clotting.

How it's Diagnosed: videos
Coagulation tests (prolonged activated partial thromboplastin time), factor IX activity assays, genetic testing.

Treatment:
Regular infusion of recombinant or plasma-derived factor IX concentrates; prophylactic therapy to prevent bleeding episodes.

Medications:
Factor IX concentrates (recombinant or plasma-derived), non-factor therapies (emerging treatments).

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 25,000 male births worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of hemophilia B; primarily affects males due to X-linked inheritance.

Prognosis: The expected outcome or course of the condition over time.
With treatment, individuals can lead a normal life; untreated, can result in severe disability or death.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Joint damage from repeated bleeding, inhibitor formation (antibodies to factor IX), intracranial hemorrhage.

Fragile X syndrome (FMR1 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: X-Linked Disorders

Symptoms:
intellectual disability; behavioral challenges; anxiety; hyperactivity; autistic traits; long face; large ears; macroorchidism in males

Root Cause:
Expansion of CGG repeats in the FMR1 gene leads to loss of function of FMRP protein, essential for neural development.

How it's Diagnosed: videos
Genetic testing to identify CGG repeat expansions in the FMR1 gene.

Treatment:
Supportive therapies, including special education, behavioral therapy, speech therapy, and medication for symptoms like anxiety or hyperactivity.

Medications:
Stimulants (e.g., methylphenidate ) for ADHD symptoms, selective serotonin reuptake inhibitors (SSRIs) for anxiety.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 4,000 males and 1 in 8,000 females worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of FMR1 mutations; primarily affects males, though females can have milder symptoms.

Prognosis: The expected outcome or course of the condition over time.
Variable; with support, individuals can achieve meaningful developmental milestones.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Learning difficulties, social challenges, and physical symptoms persist throughout life.

Rett syndrome (MECP2 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: X-Linked Disorders

Symptoms:
loss of acquired skills; hand-wringing movements; breathing irregularities; seizures; developmental regression; motor impairments

Root Cause:
Mutations in the MECP2 gene impair regulation of gene expression, critical for brain development.

How it's Diagnosed: videos
Clinical evaluation of developmental history and genetic testing for MECP2 mutations.

Treatment:
Symptom management through therapies (physical, occupational, speech), anticonvulsants, and supportive care.

Medications:
Antiepileptic drugs (e.g., valproate, levetiracetam ) for seizures; medications for spasticity or anxiety as needed.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 10,000 to 15,000 females; rare in males.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
De novo mutations in MECP2; no significant familial risk in most cases.

Prognosis: The expected outcome or course of the condition over time.
Life-long challenges; early intervention improves quality of life, but no cure exists.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Seizures, scoliosis, breathing difficulties, nutritional challenges.

X-linked adrenoleukodystrophy (ABCD1 gene mutation)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: X-Linked Disorders

Symptoms:
behavioral changes; progressive neurological decline; adrenal insufficiency; spasticity; vision and hearing loss

Root Cause:
Mutations in the ABCD1 gene impair peroxisomal beta-oxidation, leading to accumulation of very long-chain fatty acids (VLCFAs) in tissues.

How it's Diagnosed: videos
Elevated VLCFA levels in plasma, genetic testing for ABCD1 mutations, MRI for brain changes.

Treatment:
Adrenal hormone replacement, hematopoietic stem cell transplantation (HSCT) in early stages, supportive care.

Medications:
Corticosteroids (e.g., hydrocortisone ) for adrenal insufficiency; investigational therapies for VLCFA reduction.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 20,000 males worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of ABCD1 mutations; primarily affects males.

Prognosis: The expected outcome or course of the condition over time.
Progressive and potentially fatal; early detection and treatment can improve outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Adrenal crisis, severe neurological disability, early death without intervention.

Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Mitochondrial Disorders

Symptoms:
muscle weakness; recurrent headaches; vomiting; seizures; stroke-like episodes before age 40; hearing loss; diabetes mellitus; vision loss; cognitive decline

Root Cause:
Mutations in mitochondrial DNA (mtDNA) impair energy production in cells by affecting oxidative phosphorylation.

How it's Diagnosed: videos
Clinical assessment, brain MRI showing stroke-like lesions, muscle biopsy with ragged red fibers, and genetic testing for mtDNA mutations.

Treatment:
Symptomatic management with physical therapy, occupational therapy, and dietary supplementation (e.g., L-arginine, coenzyme Q10). Stroke prevention strategies may include arginine supplementation during acute episodes.

Medications:
No specific FDA-approved medications for MELAS; however, supplements like L-arginine and coenzyme Q10 (antioxidants and mitochondrial support therapies) are often recommended. Anticonvulsants may be prescribed for seizures (e.g., levetiracetam , a broad-spectrum anticonvulsant).

Prevalence: How common the health condition is within a specific population.
Rare, with an estimated prevalence of 1 in 10,000 to 1 in 20,000 individuals worldwide.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of mitochondrial disorders, maternally inherited mtDNA mutations.

Prognosis: The expected outcome or course of the condition over time.
Progressive disorder with varying severity; life expectancy depends on the severity of symptoms and complications.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Stroke-like episodes, seizures, hearing loss, progressive neurological decline, diabetes mellitus, and cardiomyopathy.

Leber Hereditary Optic Neuropathy (LHON)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Mitochondrial Disorders

Symptoms:
painless, acute or subacute central vision loss; blurring or clouding of vision; progressive bilateral visual impairment

Root Cause:
Mutations in mtDNA cause defective oxidative phosphorylation, leading to the degeneration of retinal ganglion cells and optic nerve.

How it's Diagnosed: videos
Clinical ophthalmologic examination, optical coherence tomography (OCT), and genetic testing for mtDNA mutations (e.g., m.11778G>A).

Treatment:
Vision aids for low vision; idebenone, an antioxidant, is used to improve outcomes in some cases.

Medications:
Idebenone (antioxidant therapy) is often prescribed; it is classified as a free radical scavenger and mitochondrial support agent.

Prevalence: How common the health condition is within a specific population.
Estimated at 1 in 50,000 individuals, with higher prevalence in males than females.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of LHON, tobacco use, alcohol abuse, and exposure to environmental toxins may trigger symptoms in carriers.

Prognosis: The expected outcome or course of the condition over time.
Variable; some patients experience partial recovery of vision, but many remain severely visually impaired.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Permanent vision loss, depression due to visual disability, and potential progression to bilateral blindness.

Myoclonic Epilepsy with Ragged-Red Fibers (MERRF)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Mitochondrial Disorders

Symptoms:
myoclonus (involuntary muscle jerks); epilepsy; ataxia; muscle weakness; hearing loss; short stature; exercise intolerance; cognitive impairment

Root Cause:
Mutations in mtDNA impair mitochondrial function, affecting energy production in muscle and nerve tissues.

How it's Diagnosed: videos
Clinical features, muscle biopsy showing ragged red fibers, and genetic testing for mtDNA mutations (e.g., m.8344A>G).

Treatment:
Symptomatic treatment including antiepileptic drugs for seizures, physical therapy, and dietary supplementation (e.g., L-carnitine, coenzyme Q10).

Medications:
Anticonvulsants like valproate or levetiracetam are used for seizure control; L-carnitine and coenzyme Q10 are used as mitochondrial support therapies.

Prevalence: How common the health condition is within a specific population.
Rare, with an estimated prevalence of 1 in 400,000 individuals.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of mitochondrial disorders and maternally inherited mtDNA mutations.

Prognosis: The expected outcome or course of the condition over time.
Progressive disease with variability in severity; life expectancy is reduced in severe cases.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Refractory epilepsy, progressive neurological decline, cardiomyopathy, and respiratory failure.

Kearns-Sayre Syndrome (KSS)

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Mitochondrial Disorders

Symptoms:
progressive external ophthalmoplegia (weakness of eye muscles); ptosis (drooping eyelids); retinal degeneration; cardiac conduction defects; ataxia; hearing loss; short stature; diabetes mellitus

Root Cause:
Large-scale deletions of mtDNA disrupt mitochondrial energy production, affecting multiple organ systems.

How it's Diagnosed: videos
Clinical features, muscle biopsy showing ragged red fibers, and genetic testing for mtDNA deletions.

Treatment:
Supportive treatment including cardiac pacing for conduction defects, hearing aids, physical therapy, and dietary supplementation (e.g., coenzyme Q10).

Medications:
No specific FDA-approved treatments; coenzyme Q10 and antioxidants like vitamin E are commonly recommended for mitochondrial support.

Prevalence: How common the health condition is within a specific population.
Rare, affecting approximately 1 in 100,000 individuals.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Sporadic occurrence, though some familial cases with mtDNA deletions have been reported.

Prognosis: The expected outcome or course of the condition over time.
Progressive disease; life expectancy depends on the severity of cardiac and neurological complications.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Complete heart block, progressive vision loss, hearing impairment, and endocrinopathies like diabetes mellitus.

Type 1 and Type 2 Diabetes Mellitus

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Polygenic and Multifactorial Disorders

Symptoms:
increased thirst and urination; unexplained weight loss; fatigue; blurred vision; slow healing sores or frequent infections; hunger (especially in type 1); tingling or numbness in extremities (especially in type 2)

Root Cause:
Type 1 is caused by autoimmune destruction of insulin-producing beta cells in the pancreas. Type 2 is due to insulin resistance and relative insulin deficiency, often influenced by genetic and environmental factors.

How it's Diagnosed: videos
Blood tests measuring fasting glucose levels, oral glucose tolerance tests (OGTT), hemoglobin A1c levels, and autoantibody tests (for Type 1).

Treatment:
Lifestyle changes (diet, exercise), blood sugar monitoring, insulin therapy (for Type 1), oral hypoglycemic agents, and sometimes insulin (for Type 2).

Medications:
Type 1

Prevalence: How common the health condition is within a specific population.
Type 1 affects about 5-10% of individuals with diabetes. Type 2 accounts for 90-95% of diabetes cases globally.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Type 1

Prognosis: The expected outcome or course of the condition over time.
Manageable with proper treatment; Type 1 requires lifelong insulin, and Type 2 can often be managed or reversed with lifestyle changes and medication.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Heart disease, stroke, kidney disease, retinopathy, neuropathy, and limb amputation due to poor circulation and infections.

Cleft Lip and/or Palate

Specialty: Genetics

Category: Single-Gene Disorders (Mendelian Inheritance)

Sub-category: Polygenic and Multifactorial Disorders

Symptoms:
visible opening in the lip and/or roof of the mouth; difficulty feeding; speech problems; ear infections and hearing loss

Root Cause:
Failure of facial structures to fuse during embryonic development due to genetic and environmental influences.

How it's Diagnosed: videos
Physical examination at birth, prenatal ultrasound in some cases.

Treatment:
Surgical correction (lip repair around 3-6 months, palate repair around 9-18 months), speech therapy, and orthodontic care.

Medications:
No direct medications; antibiotics for associated infections and analgesics post-surgery.

Prevalence: How common the health condition is within a specific population.
Affects 1 in 700 births globally, with variation based on ethnicity and geography.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history, maternal smoking or alcohol use, folic acid deficiency, certain medications during pregnancy.

Prognosis: The expected outcome or course of the condition over time.
Excellent with surgical intervention and multidisciplinary care.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Speech and language delays, dental abnormalities, psychosocial challenges.